Why Questcor Pharmaceuticals Inc. Shares Skyrocketed

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Questcor Pharmaceuticals (NASDAQ: QCOR.DL  ) , a biopharmaceutical company focused on developing therapies to treat autoimmune and inflammatory disorders, skyrocketed as much as 32% after announcing this morning that it had agreed to be acquired by Mallinckrodt (NYSE: MNK  ) .

So what: According to the terms of the deal, Mallinckrodt will divvy out $30 per share in cash and 0.897 Mallinckrodt shares in exchange for each share of Questcor. Furthermore, Mallinckrodt will also purchase unexpired Questcor stock options, bringing Questcor's total purchase price to approximately $5.6 billion, or a 27% premium to Friday's closing price. The deal, which is yet to be approved by either company's shareholders as of yet, would be immediately accretive to Mallinckrodt's 2014 earnings and would be significantly accretive thereafter.

Now what: Short-sellers in one of the most heavily short-sold stocks within the Nasdaq Composite just got their head thumped, plain and simple. The interesting thing, however, is that Questcor has backed well off its buyout price and is now trading at close to 10% below that level as of this writing. Part of that could be the double-digit decline in Mallinckrodt shares, but it also tells me that short-sellers believe the deal will either be voted down by Mallinckrodt shareholders, or that the ongoing investigation into the marketing of Acthar Gel by the Food and Drug Administration could throw a monkey wrench into the deal. Questcor's profits and cash flow have never been much of a question, but its lack of diversity -- one approved drug for 19 indications -- has always bothered me just in case something bad did happen to Acthar. As such, despite the arbitrage opportunity, I personally see far too much downside risk and too little upside reward to consider investing in Questcor here.

Questcor shares are soaring today, but even it could ultimately struggle to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 07, 2014, at 2:53 PM, AllyTheCat wrote:

    One risk is they run out of pigs to slaughter for their pituitary glands. Then again, QCOR stockholders, pigs get slaughtered, so maybe you're next.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2905552, ~/Articles/ArticleHandler.aspx, 9/1/2015 2:24:18 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,129.70 -398.33 -2.41%
S&P 500 1,921.71 -50.47 -2.56%
NASD 4,669.53 -106.98 -2.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 2:08 PM
MNK $85.01 Down -1.24 -1.43%
Mallinckrodt plc CAPS Rating: ***
QCOR.DL $0.00 Down +0.00 +0.00%
Questcor Pharmaceu… CAPS Rating: **